BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Jiang J, Chen L, Chen Y, Chen H. Exclusive enteral nutrition remodels the intestinal flora in patients with active Crohn's disease. BMC Gastroenterol 2022;22:212. [PMID: 35501724 DOI: 10.1186/s12876-022-02293-y] [Reference Citation Analysis]
2 Zielińska M, Szymaszkiewicz A, Jacenik D, Schodel L, Sałaga M, Zatorski H, Kordek R, Becker C, Krajewska WM, Fichna J. Cyclic derivative of morphiceptin Dmt-cyclo-(D-Lys-Phe-D-Pro-Asp)-NH2(P-317), a mixed agonist of MOP and KOP opioid receptors, exerts anti-inflammatory and anti-tumor activity in colitis and colitis-associated colorectal cancer in mice. Eur J Pharmacol 2020;885:173463. [PMID: 32835668 DOI: 10.1016/j.ejphar.2020.173463] [Reference Citation Analysis]
3 Judge C, Saeidi R, Sugrue K, Rabbitt L, Keogh A, Byron C, Zulquernain SA, Gleeson S, O'Toole A, Buckley M, Slattery E, Doherty G, McCarthy J. Combining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era? Inflamm Bowel Dis 2021;27:956-9. [PMID: 33544119 DOI: 10.1093/ibd/izab028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhang C, Ju J, Wu X, Yang J, Yang Q, Liu C, Chen L, Sun X. Tripterygium wilfordii Polyglycoside Ameliorated TNBS-Induced Colitis in Rats via Regulating Th17/Treg Balance in Intestinal Mucosa. J Inflamm Res 2021;14:1243-55. [PMID: 33833546 DOI: 10.2147/JIR.S293961] [Reference Citation Analysis]
5 Manzini R, Schwarzfischer M, Atrott K, Laimbacher A, Lang S, Wawrzyniak M, Rickenbacher A, Turina M, Hruz P, Lissner D, Siegmund B, Rogler G, Scharl M, Spalinger MR. Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. Inflamm Bowel Dis 2021:izab063. [PMID: 33847343 DOI: 10.1093/ibd/izab063] [Reference Citation Analysis]
6 Jakubczyk D, Leszczyńska K, Górska S. The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)-A Critical Review. Nutrients 2020;12:E1973. [PMID: 32630805 DOI: 10.3390/nu12071973] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
7 Szandruk-Bender M, Rutkowska M, Merwid-Ląd A, Wiatrak B, Szeląg A, Dzimira S, Sobieszczańska B, Krzystek-Korpacka M, Kucharska AZ, Matuszewska A, Nowak B, Piórecki N, Duda-Madej A, Walczuk U, Turniak M, Bednarz-Misa I, Sozański T. Cornelian Cherry Iridoid-Polyphenolic Extract Improves Mucosal Epithelial Barrier Integrity in Rat Experimental Colitis and Exerts Antimicrobial and Antiadhesive Activities In Vitro. Oxid Med Cell Longev 2020;2020:7697851. [PMID: 33299531 DOI: 10.1155/2020/7697851] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Hartwig O, Shetab Boushehri MA, Shalaby KS, Loretz B, Lamprecht A, Lehr CM. Drug delivery to the inflamed intestinal mucosa - targeting technologies and human cell culture models for better therapies of IBD. Adv Drug Deliv Rev 2021;175:113828. [PMID: 34157320 DOI: 10.1016/j.addr.2021.113828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Pabari RM, Tambuwala MM, Lajczak-McGinley N, Aljabali A, Kirby BP, Keely S, Ramtoola Z. Novel polyurethane based particulate formulations of infliximab reduce inflammation in DSS induced murine model of colitis - A preliminary study. Int J Pharm 2021;604:120717. [PMID: 34015378 DOI: 10.1016/j.ijpharm.2021.120717] [Reference Citation Analysis]
10 Ngo VL, Kuczma M, Maxim E, Denning TL. IL-36 cytokines and gut immunity. Immunology 2021;163:145-54. [PMID: 33501638 DOI: 10.1111/imm.13310] [Reference Citation Analysis]
11 Roberts KJ, Cubitt MF, Carlton TM, Rodrigues-Duarte L, Maggiore L, Chai R, Clare S, Harcourt K, MacDonald TT, Ray KP, Vossenkämper A, West MR, Crowe JS. Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Rep 2021;11:19422. [PMID: 34593832 DOI: 10.1038/s41598-021-97236-0] [Reference Citation Analysis]
12 Wang G, Yuan J, Luo J, Ocansey DKW, Zhang X, Qian H, Xu W, Mao F. Emerging role of protein modification in inflammatory bowel disease. J Zhejiang Univ Sci B 2022;23:173-88. [PMID: 35261214 DOI: 10.1631/jzus.B2100114] [Reference Citation Analysis]
13 Kumar N, Kuang L, Villa R, Kumar P, Mishra J. Mucosal Epithelial Jak Kinases in Health and Diseases. Mediators Inflamm 2021;2021:6618924. [PMID: 33814980 DOI: 10.1155/2021/6618924] [Reference Citation Analysis]
14 Jefremow A, Neurath MF. New agents for immunosuppression. Best Pract Res Clin Gastroenterol 2021;54-55:101763. [PMID: 34874846 DOI: 10.1016/j.bpg.2021.101763] [Reference Citation Analysis]
15 Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med 2020;9:E1323. [PMID: 32370274 DOI: 10.3390/jcm9051323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
16 Fiocchi C, Iliopoulos D. What's new in IBD therapy: An "omics network" approach. Pharmacol Res 2020;159:104886. [PMID: 32428668 DOI: 10.1016/j.phrs.2020.104886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
17 Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 2022. [PMID: 34987201 DOI: 10.1038/s41584-021-00726-8] [Reference Citation Analysis]
18 Huo LL, Sun ZR. MiR-128-3p alleviates TNBS-induced colitis through inactivating TRAF6/NF-κB signaling pathway in rats. Kaohsiung J Med Sci 2021. [PMID: 34042286 DOI: 10.1002/kjm2.12397] [Reference Citation Analysis]
19 Roda G, Dal Buono A, Argollo M, Danese S. JAK selectivity: more precision less troubles. Expert Rev Gastroenterol Hepatol 2020;14:789-96. [PMID: 32520647 DOI: 10.1080/17474124.2020.1780120] [Reference Citation Analysis]
20 Sato M, Fujii K, Takagi H, Shibuya I, Oka D, Yamaya N, Hagita H, Matsumoto M, Inagaki K. Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 34463880 DOI: 10.1007/s10620-021-07237-2] [Reference Citation Analysis]
21 Deepak P, Ludwig DR, Fidler JL, Guglielmo FF, Bruining DH. Medical and Endoscopic Management of Crohn Disease. Top Magn Reson Imaging 2021;30:43-61. [PMID: 33528211 DOI: 10.1097/RMR.0000000000000267] [Reference Citation Analysis]
22 Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? EBioMedicine 2021;66:103293. [PMID: 33813134 DOI: 10.1016/j.ebiom.2021.103293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Caviglia GP, Rosso C, Stalla F, Rizzo M, Massano A, Abate ML, Olivero A, Armandi A, Vanni E, Younes R, Fagoonee S, Pellicano R, Astegiano M, Saracco GM, Bugianesi E, Ribaldone DG. On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. J Clin Med 2020;9:E800. [PMID: 32183476 DOI: 10.3390/jcm9030800] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
24 Yu T, Wang Z, Jie W, Fu X, Li B, Xu H, Liu Y, Li M, Kim E, Yang Y, Cho JY. The kinase inhibitor BX795 suppresses the inflammatory response via multiple kinases. Biochemical Pharmacology 2020;174:113797. [DOI: 10.1016/j.bcp.2020.113797] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
25 Polak K, Bergler-Czop B, Szczepanek M, Wojciechowska K, Frątczak A, Kiss N. Psoriasis and Gut Microbiome-Current State of Art. Int J Mol Sci 2021;22:4529. [PMID: 33926088 DOI: 10.3390/ijms22094529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Escudero-Hernández C, van Beelen Granlund A, Bruland T, Sandvik AK, Koch S, Østvik AE, Münch A. Transcriptomic Profiling of Collagenous Colitis Identifies Hallmarks of Nondestructive Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol 2021;12:665-87. [PMID: 33930606 DOI: 10.1016/j.jcmgh.2021.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Moon SY, Kim KD, Yoo J, Lee JH, Hwangbo C. Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models. Molecules 2021;26:2824. [PMID: 34068714 DOI: 10.3390/molecules26092824] [Reference Citation Analysis]
28 Zhang H, Wang Y, Su Y, Fang X, Guo W. The alleviating effect and mechanism of Bilobalide on ulcerative colitis. Food Funct 2021;12:6226-39. [PMID: 34096560 DOI: 10.1039/d1fo01266e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]